These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 32377955

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M, Choi Y, Eisenberg R, Rao D, Tolu S, Gao J, Mowrey W, Billett HH.
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
    Amin A, Keshishian A, Dina O, Dhamane A, Nadkarni A, Carda E, Russ C, Rosenblatt L, Mardekian J, Yuce H, Baker CL.
    J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
    [Abstract] [Full Text] [Related]

  • 8. Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding.
    Pignatelli P, Pastori D, Bartimoccia S, Menichelli D, Vicario T, Nocella C, Carnevale R, Violi F.
    Pharmacol Res; 2016 Nov; 113(Pt A):484-489. PubMed ID: 27693274
    [Abstract] [Full Text] [Related]

  • 9. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.
    Kerneis M, Yee MK, Mehran R, Nafee T, Bode C, Halperin JL, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Fox KAA, Gibson CM.
    Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data.
    Costa OS, Beyer-Westendorf J, Ashton V, Milentijevic D, Moore KT, Bunz TJ, Coleman CI.
    Curr Med Res Opin; 2020 Jul; 36(7):1081-1088. PubMed ID: 32347755
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW.
    J Am Coll Cardiol; 2013 Feb 12; 61(6):651-8. PubMed ID: 23391196
    [Abstract] [Full Text] [Related]

  • 13. Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation-Related Mild Ischemic Stroke: A Randomized Clinical Trial.
    Hong KS, Kwon SU, Lee SH, Lee JS, Kim YJ, Song TJ, Kim YD, Park MS, Kim EG, Cha JK, Sung SM, Yoon BW, Bang OY, Seo WK, Hwang YH, Ahn SH, Kang DW, Kang HG, Yu KH, Phase 2 Exploratory Clinical Study to Assess the Effects of Xarelto (Rivaroxaban) Versus Warfarin on Ischemia, Bleeding, and Hospital Stay in Acute Cerebral Infarction Patients With Non-valvular Atrial Fibrillation (Triple AXEL) Study Group.
    JAMA Neurol; 2017 Oct 01; 74(10):1206-1215. PubMed ID: 28892526
    [Abstract] [Full Text] [Related]

  • 14. Circadian variations in laboratory measurements of coagulation assays after administration of rivaroxaban or warfarin in patients with nonvalvular atrial fibrillation.
    Hitaka Y, Ogawa M, Zhang B, Goto S, Nagata Y, Morii J, Imaizumi S, Yasuda T, Matsumoto N, Matsunaga A, Saku K.
    J Cardiol; 2016 Dec 01; 68(6):529-535. PubMed ID: 26987789
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of rivaroxaban and dabigatran on global hemostasis in patients with atrial fibrillation.
    Petkovic A, Al-Khalili F, Antovic A, Ammar M, Pruner I, Vranic A, Soutari N, Zdravkovic N, Malmström RE, Jakovljevic V, Antovic JP.
    Blood Coagul Fibrinolysis; 2020 Jun 01; 31(4):243-252. PubMed ID: 32141885
    [Abstract] [Full Text] [Related]

  • 17. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.
    Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR, Mackie IJ, Clawson S, Sylvestre Y, Machin SJ, Bertolaccini ML, Ruiz-Castellano M, Muirhead N, Doré CJ, Khamashta M, Isenberg DA, RAPS trial investigators.
    Lancet Haematol; 2016 Sep 01; 3(9):e426-36. PubMed ID: 27570089
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.
    Semeraro F, Incampo F, Ammollo CT, Dellanoce C, Paoletti O, Testa S, Colucci M.
    Thromb Res; 2016 Feb 01; 138():22-29. PubMed ID: 26826504
    [Abstract] [Full Text] [Related]

  • 20. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ, San Agustin K, DeAngelo J, Campbell AM.
    Ann Pharmacother; 2020 Apr 01; 54(4):344-350. PubMed ID: 31672028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.